Bevonium methylsulfate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 204920

CAS#: 5205-82-3 (methylsulfate)

Description: Bevonium methylsulfate, also known as CG201, is an antimuscarinic agent.

Chemical Structure

Bevonium methylsulfate
CAS# 5205-82-3 (methylsulfate)

Theoretical Analysis

MedKoo Cat#: 204920
Name: Bevonium methylsulfate
CAS#: 5205-82-3 (methylsulfate)
Chemical Formula: C23H31NO7S
Exact Mass:
Molecular Weight: 465.56
Elemental Analysis: C, 59.34; H, 6.71; N, 3.01; O, 24.06; S, 6.89

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 33371-53-8 (cation)   5205-82-3 (methylsulfate)    

Synonym: CG201; CG 201; CG-201; Bevonium methylsulfate; Acabel; Piribenzil methosulfate; Piribenzil methyl sulfate; Bevonium metilsulfate.

IUPAC/Chemical Name: 2-((2-hydroxy-2,2-diphenylacetoxy)methyl)-1,1-dimethylpiperidin-1-ium methyl sulfate.


InChi Code: InChI=1S/C22H28NO3.CH4O4S/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19;1-5-6(2,3)4/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1

SMILES Code: C[N+]1(C)C(COC(C(C2=CC=CC=C2)(O)C3=CC=CC=C3)=O)CCCC1.O=S(OC)([O-])=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 465.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Stall L, Lee J, McCullough M, Nsrouli-Maktabi H, Spies JB. Effectiveness of elective unilateral uterine artery embolization: a case-control study. J Vasc Interv Radiol. 2011 May;22(5):716-22. PubMed PMID: 21514525.

2: Hu NN, Kaw D, McCullough MF, Nsouli-Maktabi H, Spies JB. Menopause and menopausal symptoms after ovarian artery embolization: a comparison with uterine artery embolization controls. J Vasc Interv Radiol. 2011 May;22(5):710-715.e1. PubMed PMID: 21514524.

3: Costantino M, Lee J, McCullough M, Nsouli-Maktabi H, Spies JB. Bilateral versus unilateral femoral access for uterine artery embolization: results of a randomized comparative trial. J Vasc Interv Radiol. 2010 Jun;21(6):829-35; quiz 835. Epub 2010 Apr 15. Erratum in: J Vasc Interv Radiol. 2010 Nov;21(11):1786. Nsrouli-Maktabi, Hala [corrected to Nsouli-Maktabi, Hala]. PubMed PMID: 20399113.

4: Banovac F, Cheng P, Campos-Nanez E, Kallakury B, Popa T, Wilson E, Abeledo H, Cleary K. Radiofrequency ablation of lung tumors in swine assisted by a navigation device with preprocedural volumetric planning. J Vasc Interv Radiol. 2010 Jan;21(1):122-9. Epub 2009 Nov 25. PubMed PMID: 19939704; PubMed Central PMCID: PMC2818540.

5: Meyer J, Nsouli-Maktabi H, Spies JB. Quality of interventional radiology literature: a review of articles published in JVIR and CVIR. J Vasc Interv Radiol. 2009 Oct;20(10):1271-6. Epub 2009 Jul 23. Review. PubMed PMID: 19631559.

6: White AM, Banovac F, Yousefi S, Slack RS, Spies JB. Uterine fibroid embolization: the utility of aortography in detecting ovarian artery collateral supply. Radiology. 2007 Jul;244(1):291-8. PubMed PMID: 17581907.

7: White AM, Banovac F, Spies JB. Patient radiation exposure during uterine fibroid embolization and the dose attributable to aortography. J Vasc Interv Radiol. 2007 Apr;18(4):573-6. PubMed PMID: 17446550.

8: Spies JB, Cornell C, Worthington-Kirsch R, Lipman JC, Benenati JF. Long-term outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: results of a multicenter study. J Vasc Interv Radiol. 2007 Feb;18(2):203-7. PubMed PMID: 17327552.

9: Yousefi S, Czeyda-Pommersheim F, White AM, Banovac F, Hahn WY, Spies JB. Repeat uterine artery embolization: indications and technical findings. J Vasc Interv Radiol. 2006 Dec;17(12):1923-9. PubMed PMID: 17185687.

10: Spies JB. Adding to our understanding of uterine fibroid embolization. AJR Am J Roentgenol. 2006 Mar;186(3):846-7. PubMed PMID: 16498119.

Additional Information